Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,035 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,952 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03613363 | Engineering Evaluation of the Helix Ventilator | completed | N/A | 20 | Philips RespironicsINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05008224 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)(KEYNOTE-C11) | completed | Phase 2 | 146 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Jun 6, 2025 |
| NCT05290155 | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies | completed | Phase 1 | 14 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05866887 | Insomnia Prevention in Children With Acute Lymphoblastic Leukemia | completed | N/A | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT03792633 | Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL | completed | Phase 2 | 106 | University of PennsylvaniaOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT03012880 | Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03448393 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | completed | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06422247 | Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy | completed | — | 307 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT02975687 | CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia | completed | Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05142371 | Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors | completed | N/A | 33 | City of Hope Medical CenterOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03870945 | Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) | completed | Phase 1 | 12 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT04696432 | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | completed | Phase 1 | 7 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT01974440 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma(SELENE) | completed | Phase 3 | 403 | Janssen Research & Development, LLCINDUSTRY | 19 | May 25, 2025 | clinicaltrials |
| NCT03190330 | A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion | completed | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT03490344 | Short Course Daratumumab in Patients With Multiple Myeloma | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04042376 | A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) | completed | Phase 4 | 17 | Janssen Research & Development, LLCINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT04062448 | A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) | completed | Phase 2 | 16 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT02519452 | A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 6 | May 23, 2025 | clinicaltrials |
| NCT03113422 | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy(PrE0403) | completed | Phase 2 | 56 | PrECOG, LLC.OTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03361748 | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma(KarMMa) | completed | Phase 2 | 149 | CelgeneINDUSTRY | 8 | May 23, 2025 | clinicaltrials |
| NCT03941860 | Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | completed | Phase 3 | 1 | National Cancer Institute (NCI)NIH | 2 | May 23, 2025 | clinicaltrials |
| NCT04317885 | A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | completed | Phase 1 | 25 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04655677 | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | completed | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT05958134 | Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL | completed | — | 600 | AstraZenecaINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT06005337 | Supporting Parents to Choose Wisely | completed | N/A | 174 | University of AlbertaOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT04938141 | MEOI and HRQoL in CLL Patients Treated With BTKis | completed | — | 23 | AstraZenecaINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT04325841 | Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children | completed | Phase 2 | 2 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT04340167 | Study of Anti-CD22 CAR-T Cells Treating Leukemia Children | completed | Phase 2 | 14 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT04689659 | Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma | completed | Phase 2 | 55 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT01350245 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | completed | Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03472573 | Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT04176380 | RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma | completed | Phase 2 | 15 | Rapa Therapeutics LLCINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT04240808 | Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 1 | 10 | University of Colorado, DenverOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT00368784 | T Cell Repertoire Analysis of Immune Mediated Skin Diseases | completed | — | 426 | University of California, DavisOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT01476787 | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | CelgeneINDUSTRY | 2 | May 14, 2025 | clinicaltrials |
| NCT02580539 | A Study of the Safety and Efficacy of EBV Specific T-cell Lines(EBV-TCL-01) | completed | Phase 1 / Phase 2 | 12 | Dr. Jean-Sebastien Delisle, MD, PhDOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03583424 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05149378 | Venetoclax Based Regimen for R/R T-ALL | completed | Phase 2 | 25 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT00179673 | Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 43 | CelgeneINDUSTRY | 2 | May 13, 2025 | clinicaltrials |
| NCT03295240 | The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | completed | Early Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04402138 | Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | completed | Phase 2 | 15 | SCRI Development Innovations, LLCOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT01729091 | Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT03158688 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.(CANDOR) | completed | Phase 3 | 466 | AmgenINDUSTRY | 19 | May 9, 2025 | clinicaltrials |
| NCT04034056 | Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)(URBAN) | completed | — | 299 | Hoffmann-La RocheINDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT05962905 | Accuracy Performance Verification of the INVOS™ System in Pediatrics(INCATH) | completed | — | 110 | Medtronic - MITGINDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT06964841 | PRIMARY TESTICULAR LYMPHOMA | completed | — | 1 | Instituto Mexicano del Seguro SocialOTHER_GOV | 1 | May 9, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jun 6, 2025source: clinicaltrials